• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

转基因敲除鼠肌肉生长抑制素并不会减轻肌萎缩性脊髓侧索硬化症模型的疾病严重程度。

Transgenic inactivation of murine myostatin does not decrease the severity of disease in a model of Spinal Muscular Atrophy.

机构信息

Department of Veterinary Pathobiology, University of Missouri, Columbia, MO 65211, USA.

出版信息

Neuromuscul Disord. 2012 Mar;22(3):277-85. doi: 10.1016/j.nmd.2011.10.012. Epub 2011 Nov 10.

DOI:10.1016/j.nmd.2011.10.012
PMID:22079083
Abstract

Spinal Muscular Atrophy (SMA) is a devastating neurodegenerative disease and is a leading genetic cause of infantile death. SMA is caused by the homozygous loss of Survival Motor Neuron-1 (SMN1). The presence of a nearly identical copy gene called SMN2 has led to the development of several strategies that are designed to elevate SMN levels, and it is clear that SMN2 is an important modifier gene. However, the possibility exists that SMN-independent strategies to lessen the severity of the SMA phenotype could provide insight into disease development as well as aid in the identification of potential therapeutic targets. Muscle enhancement has been considered an interesting target for a variety of neurodegenerative diseases, including SMA. Previously we have shown in SMA mice that delivery of recombinant follistatin resulted in an extension in survival and a general lessening of disease severity. Follistatin is known to functionally block myostatin (MSTN), a potent inhibitor of muscle development. However, follistatin is a multifaceted protein involved in a variety of cellular pathways. To determine whether MSTN inhibition was the primary pathway associated with the previously reported follistatin results, we generated an animal model of SMA in which Mstn was genetically inactivated. In this report we characterize the novel SMA/Mstn model and demonstrate that Mstn inactivation does not significantly enhance muscle development in neonatal animals, nor does it result in an amelioration of the SMA phenotype.

摘要

脊髓性肌萎缩症(SMA)是一种毁灭性的神经退行性疾病,是婴儿死亡的主要遗传原因。SMA 是由运动神经元存活 1(SMN1)的纯合缺失引起的。存在一个几乎相同的拷贝基因,称为 SMN2,这导致了几种旨在提高 SMN 水平的策略的发展,很明显,SMN2 是一个重要的修饰基因。然而,存在一种可能性,即不依赖于 SMN 的策略可以减轻 SMA 表型的严重程度,这可能为疾病的发展提供了新的思路,并有助于确定潜在的治疗靶点。肌肉增强一直被认为是各种神经退行性疾病的一个有趣的靶点,包括 SMA。我们之前已经在 SMA 小鼠中表明,重组卵泡抑素的递送导致了生存时间的延长和疾病严重程度的普遍减轻。卵泡抑素已知能够功能性地阻断肌肉生长抑制素(MSTN),MSTN 是肌肉发育的一种有效抑制剂。然而,卵泡抑素是一种涉及多种细胞途径的多功能蛋白。为了确定 MSTN 抑制是否是与之前报道的卵泡抑素结果相关的主要途径,我们生成了一种 SMA 的动物模型,其中 Mstn 被基因失活。在本报告中,我们描述了新型 SMA/Mstn 模型,并证明 MSTN 失活不会显著增强新生动物的肌肉发育,也不会改善 SMA 表型。

相似文献

1
Transgenic inactivation of murine myostatin does not decrease the severity of disease in a model of Spinal Muscular Atrophy.转基因敲除鼠肌肉生长抑制素并不会减轻肌萎缩性脊髓侧索硬化症模型的疾病严重程度。
Neuromuscul Disord. 2012 Mar;22(3):277-85. doi: 10.1016/j.nmd.2011.10.012. Epub 2011 Nov 10.
2
SAHA ameliorates the SMA phenotype in two mouse models for spinal muscular atrophy.SAHA 改善了两种脊髓性肌萎缩症小鼠模型的 SMA 表型。
Hum Mol Genet. 2010 Apr 15;19(8):1492-506. doi: 10.1093/hmg/ddq023. Epub 2010 Jan 22.
3
Development and characterization of an SMN2-based intermediate mouse model of Spinal Muscular Atrophy.开发并鉴定基于 SMN2 的中间型脊髓性肌萎缩症小鼠模型。
Hum Mol Genet. 2013 May 1;22(9):1843-55. doi: 10.1093/hmg/ddt037. Epub 2013 Feb 5.
4
Delivery of recombinant follistatin lessens disease severity in a mouse model of spinal muscular atrophy.重组卵泡抑素的递送可减轻脊髓性肌萎缩小鼠模型中的疾病严重程度。
Hum Mol Genet. 2009 Mar 15;18(6):997-1005. doi: 10.1093/hmg/ddn426. Epub 2008 Dec 12.
5
Pharmacologically induced mouse model of adult spinal muscular atrophy to evaluate effectiveness of therapeutics after disease onset.用于评估疾病发作后治疗药物有效性的药理学诱导成年脊髓性肌萎缩小鼠模型。
Hum Mol Genet. 2016 Mar 1;25(5):964-75. doi: 10.1093/hmg/ddv629. Epub 2016 Jan 11.
6
The effect of the DcpS inhibitor D156844 on the protective action of follistatin in mice with spinal muscular atrophy.DcpS抑制剂D156844对卵泡抑素在脊髓性肌萎缩症小鼠中的保护作用的影响。
Neuromuscul Disord. 2015 Sep;25(9):699-705. doi: 10.1016/j.nmd.2015.05.008. Epub 2015 May 27.
7
Identification of a battery of tests for drug candidate evaluation in the SMNDelta7 neonate model of spinal muscular atrophy.在脊髓性肌萎缩症的SMNDelta7新生儿模型中鉴定用于药物候选物评估的一系列测试。
Exp Neurol. 2008 Jul;212(1):29-43. doi: 10.1016/j.expneurol.2008.02.025. Epub 2008 Mar 18.
8
Intravenous scAAV9 delivery of a codon-optimized SMN1 sequence rescues SMA mice.静脉注射 scAAV9 递送优化密码子的 SMN1 序列可拯救 SMA 小鼠。
Hum Mol Genet. 2011 Feb 15;20(4):681-93. doi: 10.1093/hmg/ddq514. Epub 2010 Nov 30.
9
Normalization of Patient-Identified Plasma Biomarkers in SMNΔ7 Mice following Postnatal SMN Restoration.出生后SMN恢复后SMNΔ7小鼠中患者识别的血浆生物标志物的正常化
PLoS One. 2016 Dec 1;11(12):e0167077. doi: 10.1371/journal.pone.0167077. eCollection 2016.
10
Neurodevelopmental consequences of Smn depletion in a mouse model of spinal muscular atrophy.脊髓性肌萎缩症小鼠模型中运动神经元存活基因缺失的神经发育后果。
J Neurosci Res. 2010 Jan;88(1):111-22. doi: 10.1002/jnr.22189.

引用本文的文献

1
Myostatin Modulation in Spinal Muscular Atrophy: A Systematic Review of Preclinical and Clinical Evidence.脊髓性肌萎缩症中的肌生成抑制素调节:临床前和临床证据的系统评价
Int J Mol Sci. 2025 Jun 18;26(12):5858. doi: 10.3390/ijms26125858.
2
Muscle: an independent contributor to the neuromuscular spinal muscular atrophy disease phenotype.肌肉:神经肌肉型脊髓性肌肉萎缩症表型的独立贡献者。
JCI Insight. 2023 Sep 22;8(18):e171878. doi: 10.1172/jci.insight.171878.
3
Advances and limitations for the treatment of spinal muscular atrophy.脊髓性肌萎缩症治疗的进展与局限。
BMC Pediatr. 2022 Nov 3;22(1):632. doi: 10.1186/s12887-022-03671-x.
4
Inhibition of myostatin and related signaling pathways for the treatment of muscle atrophy in motor neuron diseases.抑制肌肉生长抑制素和相关信号通路治疗运动神经元疾病中的肌肉萎缩。
Cell Mol Life Sci. 2022 Jun 21;79(7):374. doi: 10.1007/s00018-022-04408-w.
5
Therapy development for spinal muscular atrophy: perspectives for muscular dystrophies and neurodegenerative disorders.脊髓性肌萎缩症的治疗进展:对肌肉萎缩症和神经退行性疾病的展望
Neurol Res Pract. 2022 Jan 4;4(1):2. doi: 10.1186/s42466-021-00162-9.
6
In Search of a Cure: The Development of Therapeutics to Alter the Progression of Spinal Muscular Atrophy.寻找治愈方法:改变脊髓性肌萎缩症进展的治疗方法的发展
Brain Sci. 2021 Feb 5;11(2):194. doi: 10.3390/brainsci11020194.
7
Myostatin inhibition in combination with antisense oligonucleotide therapy improves outcomes in spinal muscular atrophy.肌抑素抑制联合反义寡核苷酸疗法改善脊髓性肌萎缩症的预后。
J Cachexia Sarcopenia Muscle. 2020 Jun;11(3):768-782. doi: 10.1002/jcsm.12542. Epub 2020 Feb 7.
8
Motor Neuron Gene Therapy: Lessons from Spinal Muscular Atrophy for Amyotrophic Lateral Sclerosis.运动神经元基因治疗:脊髓性肌萎缩症对肌萎缩侧索硬化症的启示
Front Mol Neurosci. 2017 Dec 7;10:405. doi: 10.3389/fnmol.2017.00405. eCollection 2017.
9
Therapeutic strategies for spinal muscular atrophy: SMN and beyond.脊髓性肌萎缩症的治疗策略:生存运动神经元蛋白及其他
Dis Model Mech. 2017 Aug 1;10(8):943-954. doi: 10.1242/dmm.030148.
10
Activin Receptor Type IIB Inhibition Improves Muscle Phenotype and Function in a Mouse Model of Spinal Muscular Atrophy.抑制IIB型激活素受体可改善脊髓性肌萎缩小鼠模型的肌肉表型和功能。
PLoS One. 2016 Nov 21;11(11):e0166803. doi: 10.1371/journal.pone.0166803. eCollection 2016.